Vesicles

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Medical emergencies, Acute pain, Traumatology, Vesicles, Cells, Extracellular vesicle, Vesicle, Major trauma, Coagulopathy, Injury, Shock

LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic” was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).

Key Points: 
  • The publication titled, Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).
  • The military continues to look for therapeutics that can be delivered in the field to stabilize wounded warriors.
  • While cell therapy held promise in that arena, a lyophilized product that does not require ultra-cold storage is preferable.
  • The goal of the study was to determine the therapeutic potential of CDC-EVs in a rat model of acute traumatic coagulopathy induced by polytrauma and hemorrhagic shock.

Kanazawa University research: Regulators for extracellular vesicle production

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Biology, Cell biology, Organelles, Vesicles, Membrane biology, Vesicle, Extracellular vesicle, Secretion

KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.

Key Points: 
  • KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.
  • For the development of therapies, regulators that can inhibit the secretion of specific EVs, without severe side effects, are therefore needed.
  • By screening a large set of biomolecular compounds, Rikinari Hanayama from Kanazawa University and colleagues have now identified 4 potential regulators (1 inhibitor and 3 activators) for EV secretion for a variety of cells.
  • Rikinari Hanayama from Kanazawa University and colleagues have now screened more than 1500 biochemical compounds for their use as regulators of EV secretion either inhibiting or activating the process.

Kanazawa University research: Regulators for extracellular vesicle production

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Biology, Cell biology, Organelles, Vesicles, Membrane biology, Vesicle, Extracellular vesicle, Secretion

KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.

Key Points: 
  • KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.
  • For the development of therapies, regulators that can inhibit the secretion of specific EVs, without severe side effects, are therefore needed.
  • By screening a large set of biomolecular compounds, Rikinari Hanayama from Kanazawa University and colleagues have now identified 4 potential regulators (1 inhibitor and 3 activators) for EV secretion for a variety of cells.
  • Rikinari Hanayama from Kanazawa University and colleagues have now screened more than 1500 biochemical compounds for their use as regulators of EV secretion either inhibiting or activating the process.

Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

Retrieved on: 
Wednesday, July 7, 2021
Life sciences, Biotechnology, Branches of biology, Specialty drugs, Exosome, Vesicles, Biopharmaceutical

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021.

Key Points: 
  • CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021.
  • Details are as follows:
    Live webcasts of the virtual panel discussions will be available on the Investors & Media section of the Codiak website at www.codiakbio.com .
  • Archived replays will be available for approximately 30 days following the events.
  • Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Global Exosomes Pipeline Insight Report 2021: Insights on Approx 50+ Companies and 70+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Health, Genetics, Stem cells, Pharmaceutical, Clinical trials, Branches of biology, Vesicles, Exosome

This "Exosomes - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 70+ pipeline drugs in Exosomes pipeline landscape.

Key Points: 
  • This "Exosomes - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 70+ pipeline drugs in Exosomes pipeline landscape.
  • The intrinsic properties of exosomes in regulating complex intracellular pathways have advanced their potential utility in controlling many diseases, including neurodegenerative conditions and cancer.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D.
  • This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.

Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

Retrieved on: 
Wednesday, June 2, 2021
Life sciences, Biotechnology, Biology, Specialty drugs, Exosome, Vesicles, Biopharmaceutical

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference.

Key Points: 
  • CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference.
  • Details are as follows:
    A live webcast of the virtual fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com .
  • An archived replay will be available for approximately 30 days following the fireside chat.
  • Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Exopharm (EX1): Initiation - All the parts for drug delivery development

Retrieved on: 
Monday, May 31, 2021
Branches of biology, Vesicles, Cell biology, Cells, Extracellular vesicle, Vesicle, EV, Exosome, Draft:Exopharm

We are initiating research on Exopharm, a company focused on providing solutions for the development of targeted therapeutics using extracellular vesicles (EVs).

Key Points: 
  • We are initiating research on Exopharm, a company focused on providing solutions for the development of targeted therapeutics using extracellular vesicles (EVs).
  • Its goal is to out-license this platform to one or more major pharmaceutical partners for the development of EV-based drugs.
  • EVs are small packets of plasma membrane that bud from a range of different cell types.
  • They were initially studied as therapeutics in their own right (ie nave EVs), but are also of great interest in drug delivery (engineered EVs).

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Biology, RNA, Vesicles, Medical tests, Exosome, Gene expression, RNA vaccine, Messenger RNA, Vaccine

\xe2\x80\x9cThese data demonstrated that our exosome-based, multivalent mRNA vaccine elicited long-lasting cellular and humoral responses to both the N and S proteins.

Key Points: 
  • \xe2\x80\x9cThese data demonstrated that our exosome-based, multivalent mRNA vaccine elicited long-lasting cellular and humoral responses to both the N and S proteins.
  • For additional details regarding the ISEV 10th Annual Meeting.
  • Our current focus is on the development of exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases.
  • There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements.

Vesigen Therapeutics Presents Data on Recent Advances to its Engineered ARMMs Therapeutic Delivery Platform at ISEV 2021

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Biology, Vesicles, Cell biology, Membrane biology, Medical diagnosis, Microvesicles, Nanotechnology, Vesicle, Extracellular vesicle, International Society for Extracellular Vesicles

b'CAMBRIDGE, Mass., May 18, 2021 /PRNewswire/ -- Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated delivery platform, today announced new data supporting the therapeutic potential of ARRDC1 Mediated Microvesicles (ARMMs) as vehicles for intracellular delivery of macromolecules.

Key Points: 
  • b'CAMBRIDGE, Mass., May 18, 2021 /PRNewswire/ -- Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated delivery platform, today announced new data supporting the therapeutic potential of ARRDC1 Mediated Microvesicles (ARMMs) as vehicles for intracellular delivery of macromolecules.
  • Data will be shared in two virtual poster presentations at the 2021 International Society for Extracellular Vesicles (ISEV) Annual Meeting occurring May 18-21.
  • The presentations will highlight ARMMs payloading, purification and characterization, including demonstration of cellular uptake and intracellular cargo activity.
  • Vesigen will advance the ARMMs platform to develop innovative medicines for patients through an exclusive license agreement with Harvard University.\n'

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 13, 2021
Life sciences, Branches of biology, Biotechnology, Exosome, Vesicles, Biopharmaceutical

Management will host a webcast and conference call at 4:30 p.m. today after market.\n\xe2\x80\x9cIn the first quarter, we made significant progress across our clinical and preclinical programs.

Key Points: 
  • Management will host a webcast and conference call at 4:30 p.m. today after market.\n\xe2\x80\x9cIn the first quarter, we made significant progress across our clinical and preclinical programs.
  • Most notably, we recently executed an exclusive, worldwide licensing agreement with Johns Hopkins University which allows Capricor to continue the expansion of our engineered exosome platform technology,\xe2\x80\x9d said Linda Marb\xc3\xa1n, Ph.D., CEO, Capricor Therapeutics.
  • While this evaluation is ongoing, we are encouraged by the continued interest and we look forward to updating investors in the quarter ahead.
  • Marb\xc3\xa1n continued, \xe2\x80\x9cCapricor has worked diligently to build our exosome platform to deliver biologics, primarily nucleic acids.